- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04192344
En studie för att bedöma säkerheten, tolerabiliteten och farmakokinetiken för ABSK-021 hos patienter med avancerad solid tumör
En öppen fas 1-studie av ABSK021 för att bedöma säkerhet, tolerabilitet och farmakokinetik hos patienter med avancerad solid tumör
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study will start with a dose escalation part of single-agent ABSK021 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability. The expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Siqing Fu, MD
- Telefonnummer: (713)792-4318
- E-post: siqingfu@mdanderson.org
Studera Kontakt Backup
- Namn: YUAN LU
- Telefonnummer: +86-21-68910052
- E-post: clinical@abbisko.cn
Studieorter
-
-
California
-
Beverly Hills, California, Förenta staterna, 90212
- Aktiv, inte rekryterande
- Precision NextGen Oncology
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80218-1238
- Avslutad
- SCRI at HealthOne
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Avslutad
- The Winship Cancer Institute of Emory University
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Avslutad
- MD Anderson Cancer Center
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina
- Rekrytering
- Beijing Jishuitan Hospital
-
Kontakt:
- Xiaohui Niu, MD
-
Huvudutredare:
- Xiaohui Niu, MD
-
-
Guangzhou
-
Guangdong, Guangzhou, Kina
- Aktiv, inte rekryterande
- The First Affiliated Hospital of Sun Yat-sen University
-
-
Hebei
-
Shijiazhuang, Hebei, Kina
- Avslutad
- Hebei Medical University Third Hospital
-
-
Henan
-
Zhengzhou, Henan, Kina
- Avslutad
- The First Affiliated Hospital of Zhengzhou Universtity
-
Zhengzhou, Henan, Kina
- Aktiv, inte rekryterande
- Henan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina
- Aktiv, inte rekryterande
- Nanjing Drum Tower Hospital
-
Nanjing, Jiangsu, Kina
- Aktiv, inte rekryterande
- Jiangsu Province Hospital
-
-
Liaoning
-
Shenyang, Liaoning, Kina
- Avslutad
- Liaoning Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina
- Avslutad
- Huashan Hospital of Fudan University
-
Shanghai, Shanghai Municipality, Kina
- Avslutad
- Shanghai Sixth People's Hospital
-
-
Shanxi
-
Xian, Shanxi, Kina
- Aktiv, inte rekryterande
- Xi'an Hong Hui Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- Rekrytering
- West China Hospital of Sichuan University
-
Kontakt:
- Yong Zhou, MD
-
Huvudutredare:
- Yong Zhou, MD
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- Rekrytering
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Kontakt:
- Zhaoming Ye, MD
-
Huvudutredare:
- Zhaoming Ye, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed solid tumors that have progressed on or intolerant to standard therapy or whom no standard therapy exists
- ECOG (electrocorticogram) performance status 0~1
- Life expectancy ≥ 3 months
- Adequate organ function and bone marrow function
For patients with tenosynovial giant cell tumor (TGCT) :
- A diagnosis of TGCT [i ncluding pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT TS) (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pathologist,and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a multi disciplinary tumor board);
- Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2 cm is required), assessed from MRI scans;
- Others
For Adolescent Cohort (China only):
- Patient and/or legally acceptable representative should understand, sign, and date the written voluntary informed consent form prior to screening.
- Adolescents≥ 12 years of age and < 18 years at the time of informed consent.
- Body weight ≥ 40kg.
- A diagnosis of TGCT [including pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT-TS)] (i) that has been histologically confirmed either by local laboratory, and (ii) unresectable, defined as confirmed by assessment by at least two clinical experts (including at least one independent expert who is not part of the trial conduct), meeting one of the following 2 requirements: ①located in a complex anatomical site, is extensively invasive, and cannot be completely resected; ②surgical operation may cause dysfunction or serious complications.
- Measurable disease as defined by RECIST v1.1 (with at least 1 lesion ≥ 2 cm is required), assessed by MRI scans in local site prior to dosing.
- Others
Exclusion Criteria:
- Known allergy or hypersensitivity to any component of the investigational drug product Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating factor 1 receptor) pathway inhibitors
- Known additional malignancy that is progressing or required active treatment within 3 years of the first dose of study treatment
- Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication
- Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment)
- Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence
- Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤2 severity (CTCAE v5.0) with the exception of alopecia and vitiligo
- Prior corticosteroids as anti-cancer therapy within a minimum of 2 weeks of the first dose of study drug
- Concomitant use of strong inhibitors or inducers of CYP3A4
- Active central nervous system (CNS) metastases
- Impaired cardiac function or clinically significant cardiac disease
- Patients with Gilbert's Syndrome or other underlying conditions that may lead to a greater likelihood of developing LFT(liver function test) abnormalities during the study
- Known human immunodeficiency virus or active hepatitis B, or active hepatitis C infection
- Refractory/uncontrolled ascites or pleural effusion
- Pregnant or nursing
For patients with tenosynovial giant cell tumor (TGCT) :
- Known allergy or hypersensitivity to any component of the investigational drug product
- For expansion part, previous treatment with CSF 1/CSF 1R pathway inhibitors (not applicable for TGCT patients in US)
- Others
For Adolescent Cohort (China only):
- Known allergy or hypersensitivity to any component of the investigational drug product.
- Previous treatment with highly selective inhibitors targeting CSF-1/CSF-1R prior to first dosing. However, patients who have received prior treatment with multi-kinase inhibitors that include the CSF-1/CSF-1R pathway are allowed, such as Imatinib and Nilotinib.
- Know additional malignancy that required active treatment and may affect the patient's participation in the study or affect the outcome of the study as assessed by the Investigator. Exceptions include cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and other carcinoma in situ.
- Others
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ABSK021
Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by"3+3" escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles. |
ABSK021 oral capsule |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence and Severity of AEs
Tidsram: Through study completion, an average of 6 months
|
Adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs) |
Through study completion, an average of 6 months
|
|
Incidence of DLTs
Tidsram: At the end of Cycle 1 (each cycle is 28 days)
|
DLT(dose-limiting toxicity) |
At the end of Cycle 1 (each cycle is 28 days)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PFS
Tidsram: From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
Progression-Free Survival (PFS) |
From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
|
DoR
Tidsram: From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
Duration of Response (DoR) |
From date of enrollment until the date of first documented progression or death, assessed up to 12 months
|
|
DCR
Tidsram: 24 weeks post-dose
|
Disease Control Rate (DCR) |
24 weeks post-dose
|
|
Cmax
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The peak plasma concentration of a drug after administration |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
|
tmax
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Time to reach Cmax |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
|
Bioavailability
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The systemically available fraction of a drug |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
|
Elimination half-life
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
The time required for the concentration of the drug to reach half of its original value |
Pre-dose and multiple timepoints (up to 72 hours) post-dose
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Siqing Fu, MD, M.D. Anderson Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ABSK021-101
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .